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1Current ACIP recommendations for MenB vaccines
 In February 2015, ACIP recommended that persons aged ≥10 years at increased risk for 
serogroup B meningococcal disease receive a MenB primary series (Routine)
– Includes persons with complement deficiency, complement inhibitor use, asplenia, 
microbiologists and individuals exposed during an outbreak
 In June 2015, ACIP recommended that adolescents aged 16–23 years may be vaccinated 
with a MenB primary series based on individual clinical decision-making (preferred age of 
16–18 years) (Clinical Decision Making)
2Proposed language for VOTE #1
For persons aged ≥10 years with complement deficiency, complement inhibitor use, 
asplenia, or who are microbiologists:
 ACIP recommends a MenB booster dose 1 year following completion of a MenB
primary series followed by MenB booster doses every 2-3 years thereafter, for as 
long as increased risk remains.
For persons aged ≥10 years determined by public health officials to be at increased risk 
during an outbreak:
• ACIP recommends a one-time booster dose if it has been ≥1 year since completion of 
a MenB primary series.
• A booster dose interval of ≥6 months may be considered by public health officials 
depending on the specific outbreak, vaccination strategy, and projected duration of 
elevated risk.
3Additional Guidance 
 These recommendations do not apply to persons who previously completed a MenB 
primary series as an adolescent based on individual clinical decision-making and who are 
not at increased risk for serogroup B meningococcal disease.
 MenB vaccines are not interchangeable. The same product must be used for all doses.
 Collection of safety and effectiveness data for repeated booster doses of MenB vaccine in 
persons at increased risk for serogroup B meningococcal disease is needed for the ongoing 
evaluation of these recommendations by the ACIP Meningococcal Vaccines Work Group.  
